anastrazole

ApprovedSmall molecule

AstraZeneca

anastrazole is one of 167 small molecule programs targeting Weight loss. It is currently in Approved.

Indications

Total Trials

Active Trials

166

Competitors

Pipeline

Status by Indication[3][1]

Indication

Weight LossActive, not recruiting

Inguinal HerniaRecruiting

Breast CancerActive, not recruiting

EndometriosisActive, not recruiting

GrowthActive, not recruiting

Weight LossApproved

Active, not recruiting

Inguinal HerniaPhase 1

Recruiting

Breast CancerPhase 3

Active, not recruiting

EndometriosisApproved

Active, not recruiting

GrowthPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

anastrazole

AstraZeneca

Approved

6 2

Trodelvy

Gilead

Preclinical

37 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 7

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Chantix

PPrism Pharmaceuticals

Preclinical

1 10

Avastin

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Inguinal Hernia

NCT07604272

Q3 2030

Phase 2Recruiting

Breast Cancer

NCT06953882

Q4 2033

Phase 2Recruiting

Ductal Carcinoma in Situ

NCT06075953

Clinical

Trials by Indication[1]

Breast Cancer6 trials

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

Completed·UUniversity of Kansas Medical Center·Phase 2·NCT00921115·42 enrolled

Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00259090·120 enrolled

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

Withdrawn·MMedical College of Wisconsin·Phase 1·NCT04316169

Show 3 more trials

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Recruiting·YYale University·Phase 2·NCT06953882·140 enrolled

Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00605267·197 enrolled

A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT00022672·208 enrolled

Recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT06075953·400 enrolled

Growth1 trial

Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men

Completed·MMayo Clinic·Phase 1·NCT00309855·80 enrolled

3 more indications

Neoadjuvant1 trial

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00255463·185 enrolled

Weight loss1 trial

Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)

Completed·—·Phase 4·NCT02959853·23 enrolled

Inguinal hernia1 trial

Reversing InGuinal Hernia Trial (RIGHT Trial): The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males

Recruiting·NNorthwestern University·Phase 1·NCT07604272·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for anastrazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anastrazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anastrazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

anastrazole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2030

Q4 2033

Trials by Indication[1]

Breast Cancer6 trials

Endometriosis1 trial

Steroid1 trial

Ductal Carcinoma in Situ1 trial

Growth1 trial

Neoadjuvant1 trial

Weight loss1 trial

Inguinal hernia1 trial

References

Drug Info

Quick Facts

Related News